SLC6A1-related Neurodevelopmental Disorder · SLC6A1

What this is

SLC6A1-related neurodevelopmental disorder is caused by heterozygous loss-of-function mutations in SLC6A1, the gene on chromosome 3p25 encoding GAT-1, the brain's main GABA transporter. GAT-1 sits on the surface of neurons and astrocytes and re-uptakes the inhibitory neurotransmitter GABA from the synaptic cleft after release. Loss of one functional SLC6A1 copy reduces GAT-1 expression, which in thalamic astrocytes appears to allow extracellular GABA to accumulate and produce enhanced tonic inhibition, paradoxically generating seizures and abnormal cortical rhythms.

The clinical phenotype includes myoclonic-atonic epilepsy, generalized absence seizures (present in more than 70 percent of affected children), 2-to-4-Hz spike-wave discharges on EEG, intellectual disability, autism spectrum features, and language delay. Onset of seizures is typically between 1 and 4 years of age, and the developmental delay is often apparent earlier. The condition was first molecularly characterized in 2015 by Carvill, Heavin, Yendle, and McMahon and colleagues at the University of Washington and partner institutions, who identified pathogenic SLC6A1 mutations in approximately 4 percent of unsolved myoclonic-atonic epilepsy cases.

Estimated incidence is 2.4 to 2.9 per 100,000 births. The condition is not ultra-rare in the strictest sense; SLC6A1 is among the top ten to twenty epilepsy genes in large genomic screens, with somewhere between 1 in 30,000 and 1 in 40,000 individuals affected. Many cases remain undiagnosed because the phenotype overlaps with other epilepsy syndromes, and diagnostic exome or epilepsy-panel sequencing is required to identify the variant.

There is no approved disease-modifying therapy. Standard of care is anticonvulsant management (often valproate, lamotrigine, or ethosuximide for the absence seizures), supportive therapy, and educational accommodations for the developmental component. The seizures are often pharmaco-resistant, and the developmental disability persists into adulthood.

The case

Amber Freed and her husband Mark brought home twin sons, Maxwell and Riley, in March 2017. Riley met early developmental milestones on schedule. Maxwell did not. By approximately six months old, Maxwell was visibly behind his twin in motor and language development, and Amber, an executive in finance with no medical training, began to suspect the difference was not within normal variation.

The diagnostic workup took most of 2018. Maxwell was eventually identified through clinical exome sequencing as carrying a heterozygous missense variant in SLC6A1. The diagnosis named the condition. It produced no treatment, no clinical trial enrollment option, and no clinician with substantial experience managing the disease. The condition had been in the literature for three years.

Amber Freed left her finance career and spent the rest of 2018 educating herself about the disease, the genetics, and the therapeutic options. She concluded that a gene replacement therapy for SLC6A1, rather than waiting for a small-molecule drug discovery program that might or might not work, was the fastest plausible path to a treatment. She incorporated SLC6A1 Connect, the family-led foundation, in 2018. Her stated goal was to fund the development of a gene therapy for Maxwell's condition and, by extension, for the other children worldwide affected by the same disease.

In late 2018 she attended a gene therapy conference where Steven Gray of UT Southwestern was speaking. She had identified Gray as the academic researcher most likely to be able to develop an AAV9 vector for SLC6A1, based on his published work on the AAV9 platform for other rare brain diseases. She sat next to him in the audience, introduced herself, and persuaded him to take the case. The partnership between SLC6A1 Connect and the Gray Lab was announced publicly in October 2018.

The next two and a half years were a fundraising and preclinical-research push. Freed and SLC6A1 Connect raised more than three million dollars by the end of 2021 through community events, individual donations, and grants. The money funded the engineering of mouse models carrying both SLC6A1 knockout alleles and Maxwell's specific missense variant, the design and validation of the AAV9-SLC6A1 vector, and the preclinical experiments that would support an eventual investigational new drug application.

Maxwell, meanwhile, has continued to receive standard pediatric care for SLC6A1-related disorder. He is now in elementary school. His seizures, motor function, and cognitive trajectory are documented in the natural-history data SLC6A1 Connect has been building in parallel with the gene therapy program, so that the eventual clinical trial has the comparator data it will need.

The research

The Gray Lab's AAV9-SLC6A1 program is a particularly clean example of the academic-platform model. The vector reuses the AAV9 capsid and intrathecal administration route the Gray Lab has previously validated for giant axonal neuropathy, several Batten subtypes, Rett syndrome, hereditary spastic paraplegia type 50, and other CNS gene-therapy programs. The therapeutic cassette inserts a functional copy of the SLC6A1 coding sequence under a promoter calibrated to give the right level of GAT-1 expression in the target cell types.

A specific engineering refinement the program required is the miRARE element. miRARE, short for miRNA-Responsive Auto-Regulatory Element, is a feedback mechanism Gray's group has published that uses endogenous microRNA expression to limit transgene expression in cells that already produce sufficient endogenous protein. For SLC6A1, auto-regulation matters more than for most AAV gene therapies because GAT-1 overexpression is itself cytotoxic. Too much GAT-1 in cells that already have one functional SLC6A1 copy would over-clear synaptic GABA and produce its own neurological dysfunction. miRARE is what makes the gene-replacement strategy safe in a disease where the affected children are heterozygous.

The lead preclinical paper was published in the Journal of Clinical Investigation in late 2024, Volume 135, Issue 3, by Guo, Rioux, and colleagues, with Steven Gray as corresponding author. Neonatal intracerebroventricular administration of the AAV9-SLC6A1 vector to Slc6a1-/- mice and to Slc6a1+/- mice (the heterozygous model that more closely resembles the human disease) produced significant normalization of EEG patterns and improvement in several cognitive-behavioral phenotypes. The miRARE-regulated vector did not produce the overexpression toxicity that an unregulated vector would have produced.

In parallel with the Gray Lab program, separate SLC6A1 gene therapy and small-molecule research programs are active at Vanderbilt University Medical Center and the Cleveland Clinic. The field is now multi-institution. The redundancy is partly competitive and partly cooperative: the parallel programs increase the chance that one will reach the clinic and produce a working therapy, and the cumulative natural-history and biomarker data benefit any program that reaches a trial.

The clinical trial pathway as of 2025 has the AAV9-SLC6A1 program at advanced preclinical stages, with the Gray Lab and SLC6A1 Connect jointly preparing an investigational new drug application. The first-in-human dosing is expected within the next eighteen to thirty-six months on current trajectories, though the timeline depends on toxicology and manufacturing readiness.

What is blocking the next case

The SLC6A1 program is at a transition point that distinguishes it from the milasen-class single-patient ASO programs. The condition is too common to address one family at a time and not common enough to support a standard pharmaceutical development pipeline. The blockers are accordingly different.

Manufacturing scale is the first. A single-patient AAV trial like Pirovolakis's SPG50 program needs one batch of clinical-grade vector. A trial for SLC6A1, even at phase 1 with a small cohort, needs material for ten to thirty children, plus enough for natural-history and biomarker work. The small-batch academic GMP facilities that produced the Pirovolakis vector cannot easily scale to phase 1 commercial-readiness quantities without commercial partnership.

Regulatory bar is the second. A first-in-human dose in an n-of-many trial is reviewed under a different framework than a single-patient sponsor-investigator IND. The toxicology requirements are higher, the dose-escalation work is more formal, and the FDA's review of a phase 1 trial application takes longer than the emergency IND review of a one-person program.

Outcome measure validation is the third. The natural-history work SLC6A1 Connect and Wendy Chung's collaborator network at Boston Children's have been doing addresses this directly, but a phase 1 trial readout requires clinical endpoints that will be acceptable to the FDA at the next regulatory step. Pediatric epilepsy and developmental disability outcome measures in this age range are an active area of work.

Funding is the fourth and the one most visible to families. SLC6A1 Connect has been one of the more successful family-led foundations at raising philanthropic dollars for an ultra-rare gene therapy program. The amount needed to take the program from current preclinical readiness through phase 1, phase 2, and toward approval is substantially higher than what the foundation has raised so far. The eventual expectation is that a commercial partner will pick up the program at the late-preclinical or phase 1 stage. Negotiating that transition without diluting the family-and-foundation governance over the program is one of the open structural questions for the model.

Where this connects

The technical platform this case sits on is described in Steven Gray and the AAV9 platform for rare brain disease. The SLC6A1 program is one of roughly a dozen programs the Gray Lab has fed into preclinical or clinical evaluation, and the engineering choices that make the SLC6A1 vector safe (the miRARE auto-regulation, the AAV9 capsid, the intrathecal route) are the same engineering choices that make the other programs in the Gray Lab pipeline tractable. The pattern across the slate is the proof that the academic-platform model produces repeatable n-of-many AAV programs.

Sources

• Carvill GL, McMahon JM, Schneider A, et al. Mutations in the GABA transporter SLC6A1 cause epilepsy with myoclonic-atonic seizures. Am J Hum Genet. 2015;96(5):808-815. PMID: 25865495.
• Goodspeed K, Pérez-Palma E, Iqbal S, et al. Current knowledge of SLC6A1-related neurodevelopmental disorders. Brain Commun. 2020;2(2):fcaa170.
• Guo W, Rioux M, Bailey RM, et al; Gray SJ corresponding author. AAV9/SLC6A1 gene therapy rescues abnormal EEG patterns and cognitive behavioral deficiencies in Slc6a1-/- mice. J Clin Invest. 2025;135(3):e182235. PMID: 39589822.
• SLC6A1 Connect. Foundation history, partnership announcement, and program updates. https://slc6a1connect.org
• American Society of Gene and Cell Therapy. Meet Amber Freed. January 2021. https://asgct.org/research/news/january-2021/amber-freed-slc6a1
• Simons Searchlight. Member feature: Amber Freed looks for a gene therapy "miracle". https://www.simonssearchlight.org
• Mei D, Ricci V, Ching S, et al. SLC6A1 patient and organization perspective: founding of SLC6A1 Connect, research, and ongoing efforts. (2024 family-and-foundation perspective article in PMC.)
• CNBC. How one parent is raising money to fund research into rare disease SLC6A1. January 2020.